Category Archives: Role of Blocking IL-1 with Canakinumab for Atherosclerotic Disease

Role of Blocking IL-1 with Canakinumab for Atherosclerotic Disease

Update 09/29/2017: Here is a Storify summary of our session: https://storify.com/psufka/rheumjc-from-09-28-2017 

Our next #RheumJC session will be Thursday, September 28th.

We’ll be discussing the recently published NEJM article Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Also refer to the associated editorial in NEJM, Targeting Inflammation in Coronary Artery Disease.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.